[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565025":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":26,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Oxford","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"losartan","EXPERIMENTAL","single-dose losartan potassium (Cozaar; weight-adjusted 25mg or 50mg)",[13],"Drug: Losartan potassium",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Microcellulose placebo in identical capsule",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Losartan potassium","Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo",[9],null,{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Single tablet encapsulated identically to placebo",[15],[31],{"name":32,"affiliation":5,"role":33},"Andrea Reinecke, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","+44 01865 618320","andrea.reinecke@psych.ox.ac.uk",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Warneford Hospital, University of Oxford","RECRUITING","Oxford","Oxfordshire","OX37JX","United Kingdom","UK",{"type":49,"coordinates":50},"Point",[51,52],-1.25596,51.75222,{"lat":52,"lon":51},[55,57],{"name":32,"role":36,"phone":56,"phoneExt":26,"email":38},"01865 618320",{"name":32,"role":33,"phone":26,"phoneExt":26,"email":26},{"type":59,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[61],{"name":62,"class":63},"National Institute for Health Research, United Kingdom","OTHER_GOV","100565025","early-phase-1-losartan-and-emotional-processing-in-young-people-100565025",false,"NCT06636812","Losartan and Emotional Processing in Young People","The Effects of Single-dose Losartan on the Processing of Emotional Information in Healthy Adolescents: a Randomised Controlled Study","Inclusion Criteria:\n\n* Willing and able to provide informed consent (for 16 and 17 year olds: assent and parental\u002F legal guardian consent)\n* Non- or light-smoker (\\< 5 cigarettes a day)\n* Ability to attend appointments in Oxford with reasonable travel costs\n* Ability\u002F willingness to provide GP contact details\n\nExclusion Criteria:\n\n* Past or present DSM-5 axis-I diagnosis (based on SCID results at screening), especially severe psychiatric illness or alcohol or substance dependence\n* First-degree family member with severe psychiatric illness\n* CNS-medication last 6 weeks (including as part of another study)\n* Current blood pressure or other heart medication (especially aliskiren or beta blockers)\n* Diagnosis of intravascular fluid depletion or dehydration\n* Impaired kidney function (based on blood test at screening, cut-off 75 ml\u002Fmin\u002F1.73 m2)\n* Significant hyperkalaemia (level\\>=6mEq\u002FL in the absence of sample haemolysis will be considered significant hyperkalaemia)\n* Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90\u002F50 mmHg (in accordance with established standard definitions: DOI 10.1186\u002Fs12887-016-0633-7))\n* Body weight below 35kg (as the lower dose of 25mg of losartan only indicated from 35kg)\n* Lifetime history of epilepsy or other neurological disease (e.g. ADHD, autism)\n* Lifetime history of angioedema, renal artery stenosis, valvular heart disease, recurrent postural\u002F orthostatic hypotension\n* Lifetime history ofsystemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.\n* Significant loss of hearing that is not corrected with a hearing device Insufficient written and\u002For spoken English skills\n* Women: pregnancy, breast-feeding",true,"ALL","16 Years","20 Years",{"count":76,"type":77},60,"ESTIMATED","INTERVENTIONAL",[80],"EARLY_PHASE1","This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in young healthy volunteers.",[83],"Emotional Processing",[85,86,87],"emotional processing","anxiety","adolescents","2025-06-12",{"date":90,"type":91},"2025-06-15","ACTUAL",{"date":93,"type":91},"2024-03-07",{"date":95,"type":77},"2025-12-31",{"name":5,"class":6},1]